Jeff Masten

Chief Operating Officer • Theragent

A biotech business leader who is passionate about improving the lives of patients and their families, Jeff has dedicated his 43-year career to advancing therapies to fight cancer and other debilitating diseases. He recently joined Theragent in 2020 as Chief Operating Officer and completed the design, build, and qualification of Theragent’s state-of-the-art GMP and Pharma 4.0 Cell and Gene therapy manufacturing facility in Arcadia California. Prior to Theragent, Jeff served JUNO/BMS in a senior leadership role responsible for the preparation of the cell therapy manufacturing facility PLI and commercial licensure of Breyanzi. Today, Jeff is a champion for Theragent’s amazing staff, clients, and patients, as the company prepares to fill their capacity with exciting new therapies. Over the last 4 decades, Jeff has served in leadership positions for Eli Lily & Company, Aventis Behring, Genentech, Atara Biotherapeutics, and JUNO/BMS. He received his undergraduate degrees from Indiana University and Salisbury University in Chemistry and Business respectively.  In 2002, he received his MBA from the University of Notre Dame’s Mendoza School of Business.

Also Speaking

Justin McCue

Chief Technical Officer • Avectas

Michael E. Meyers

Vice Chairman Head of M&A and Strategic Advisory Services • H.C. Wainwright & Co

Bernd Leistler

Vice President Production • Sartorius CellGenix

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.